GT199900154A - Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas. - Google Patents

Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.

Info

Publication number
GT199900154A
GT199900154A GT199900154A GT199900154A GT199900154A GT 199900154 A GT199900154 A GT 199900154A GT 199900154 A GT199900154 A GT 199900154A GT 199900154 A GT199900154 A GT 199900154A GT 199900154 A GT199900154 A GT 199900154A
Authority
GT
Guatemala
Prior art keywords
treatment
microadenomas
adhd
parkinson
disease
Prior art date
Application number
GT199900154A
Other languages
English (en)
Inventor
Elisa Rose Jackson
Stafford Mclean
Stevin Howard Zorn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT199900154A publication Critical patent/GT199900154A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

LA PRESENTE INVENCIÒN SE REFIERE AL USO DE CIERTOS DERIVADOS DE PIRIDO(1,2A)PIRAZINA, TAMBIEN DESCRITOS COMO COMPUESTOS BISAZABICÌCLICOS Y DEFINIDO POR LA "FÒRMULA I" ABAJO INDICADA, EN EL TRATAMIENTO DE LA ENFERMEDAD DE PARKINSON, EL TRASTORNO DE HIPERACTIVIDAD CON DÈFICIT DE ATENCIÒN Y MICROADENONAS EN MAMÌFEROS, Y A COMPOSICIONES RELACIONADAS.
GT199900154A 1998-09-21 1999-09-13 Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas. GT199900154A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10119198P 1998-09-21 1998-09-21
US10386898P 1998-10-12 1998-10-12

Publications (1)

Publication Number Publication Date
GT199900154A true GT199900154A (es) 2001-03-06

Family

ID=26798000

Family Applications (1)

Application Number Title Priority Date Filing Date
GT199900154A GT199900154A (es) 1998-09-21 1999-09-13 Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.

Country Status (38)

Country Link
US (2) US6300329B1 (es)
EP (1) EP1115402A1 (es)
JP (1) JP2002526448A (es)
KR (3) KR20040054752A (es)
CN (1) CN1319013A (es)
AP (1) AP1456A (es)
AR (1) AR029739A1 (es)
AU (1) AU760230B2 (es)
BG (1) BG105445A (es)
BR (1) BR9913975A (es)
CA (1) CA2344670A1 (es)
CO (1) CO5140075A1 (es)
CZ (1) CZ20011006A3 (es)
DZ (1) DZ2894A1 (es)
EA (2) EA200301063A1 (es)
EE (1) EE200100179A (es)
GE (1) GEP20033081B (es)
GT (1) GT199900154A (es)
HN (1) HN1999000146A (es)
HR (1) HRP20010209A2 (es)
HU (1) HUP0103691A3 (es)
ID (1) ID28028A (es)
IL (2) IL141507A0 (es)
IS (1) IS5852A (es)
MA (1) MA26690A1 (es)
MY (1) MY127939A (es)
NO (1) NO20011409L (es)
NZ (1) NZ509855A (es)
OA (1) OA11653A (es)
PA (1) PA8482001A1 (es)
PE (1) PE20001084A1 (es)
PL (1) PL346904A1 (es)
SK (1) SK3592001A3 (es)
TN (1) TNSN99177A1 (es)
TR (2) TR200402083T2 (es)
TW (1) TW518225B (es)
WO (1) WO2000016777A1 (es)
YU (1) YU21701A (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1999000146A (es) * 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
WO2001068104A1 (en) * 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
GB0027020D0 (en) 2000-11-03 2000-12-20 Univ Manchester Treatment of movement disorders
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
US7132287B2 (en) 2001-06-18 2006-11-07 Psychiatric Genomics, Inc. Method for neural stem cell differentiation using 5HT-1A agonists
US20030036555A1 (en) * 2001-08-03 2003-02-20 Boehringer Ingelheim Pharma Kg Pramipexole for the treatment of ADHD
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US7737128B2 (en) * 2004-06-10 2010-06-15 The Mclean Hospital Corporation Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
EP1784199A4 (en) * 2004-08-11 2010-06-23 Mclean Hospital Corp COMPOUNDS FOR TREATING MARIHUANA DEPENDENCE, DEDUCTION AND CONSUMPTION
MY148644A (en) 2005-07-18 2013-05-15 Orion Corp New pharmaceutical compounds
TW200800306A (en) 2005-09-12 2008-01-01 Wyeth Corp Sustained-release formulation and uses thereof
GT200600414A (es) 2005-09-12 2007-09-20 Sal de glucuranato de compuesto de piperazine
GT200600416A (es) 2005-09-12 2007-09-20 Sales salicilato y gentisato de un compuesto de piperazina
US9066903B2 (en) * 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
WO2008083442A1 (en) * 2007-01-10 2008-07-17 Brc Operations Pty Limited Method for formulating combination medications for adhd
CN101318020B (zh) * 2007-06-06 2011-09-28 四川科瑞德制药有限公司 抗焦虑或/和抗抑郁的药物组合物及用途
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
GB201112987D0 (en) 2011-07-28 2011-09-14 Ge Healthcare Ltd Novel compound
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014172372A1 (en) 2013-04-15 2014-10-23 Northwestern University Treatment for dopaminergic disorders
CN104892589A (zh) 2014-03-07 2015-09-09 中国科学院上海药物研究所 一类杂环化合物、其制备方法和用途
US11426366B2 (en) 2015-05-15 2022-08-30 Arizona Board Of Regents On Behalf Of The Universsity Of Arizona Compositions and methods for treating motor disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX19222A (es) * 1989-01-23 1993-12-01 Pfizer Agentes ansioliticos bis-aza-biciclicos
WO1992000075A1 (en) * 1990-06-29 1992-01-09 Pfizer Inc. Pyridopyrazine derivatives for treating substance abuse and addiction
US5281607B1 (en) * 1992-10-08 1998-05-19 Univ New York Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases
GB9408084D0 (en) * 1994-04-23 1994-06-15 Boots Co Plc Medical treatment
MX9606450A (es) * 1994-06-14 1997-03-29 Pfizer Derivados de bencimidazolona.
US5877183A (en) * 1996-06-06 1999-03-02 Ergo Research Corporation Treatment of lipid and glucose metabolism disorders with dopamine and serotonin agonists
HN1999000146A (es) * 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.

Also Published As

Publication number Publication date
US20010034347A1 (en) 2001-10-25
MA26690A1 (fr) 2004-12-20
NO20011409D0 (no) 2001-03-20
HUP0103691A3 (en) 2003-01-28
BR9913975A (pt) 2001-06-19
ID28028A (id) 2001-05-03
KR100468340B1 (ko) 2005-01-27
GEP20033081B (en) 2003-10-27
US6608064B2 (en) 2003-08-19
YU21701A (sh) 2004-07-15
KR20040054752A (ko) 2004-06-25
IS5852A (is) 2001-02-20
JP2002526448A (ja) 2002-08-20
BG105445A (en) 2001-12-29
PE20001084A1 (es) 2000-10-18
IL141507A0 (en) 2002-03-10
MY127939A (en) 2007-01-31
HUP0103691A2 (hu) 2002-02-28
NZ509855A (en) 2003-04-29
CA2344670A1 (en) 2000-03-30
NO20011409L (no) 2001-03-28
DZ2894A1 (fr) 2003-12-15
AP2001002102A0 (en) 2001-03-31
KR20010075222A (ko) 2001-08-09
SK3592001A3 (en) 2001-12-03
CO5140075A1 (es) 2002-03-22
OA11653A (en) 2004-12-08
HN1999000146A (es) 2000-11-11
US6300329B1 (en) 2001-10-09
AR029739A1 (es) 2003-07-16
AU5383199A (en) 2000-04-10
WO2000016777A1 (en) 2000-03-30
EP1115402A1 (en) 2001-07-18
AU760230B2 (en) 2003-05-08
EA200100204A1 (ru) 2001-08-27
KR20030088512A (ko) 2003-11-19
TR200402083T2 (tr) 2004-10-21
CZ20011006A3 (cs) 2001-09-12
AP1456A (en) 2005-09-30
IL164839A0 (en) 2005-12-18
HRP20010209A2 (en) 2002-04-30
PL346904A1 (en) 2002-03-11
TR200101357T2 (tr) 2001-08-21
CN1319013A (zh) 2001-10-24
EA200301063A1 (ru) 2004-12-30
TNSN99177A1 (fr) 2005-11-10
TW518225B (en) 2003-01-21
PA8482001A1 (es) 2000-05-24
EE200100179A (et) 2002-10-15

Similar Documents

Publication Publication Date Title
GT199900154A (es) Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
UY26495A1 (es) " derivados de tiazolilamida"
GT199900070A (es) Derivados de isotiazol, utiles como agentes anticancerosos.
ES2194314T3 (es) Derivados de benzopirano sustituidos para el tratamiento de inflamaciones.
ES2193391T3 (es) Antagonistas muscarinicos.
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
PA8551001A1 (es) Nuevos compuestos
AR023363A1 (es) Compuestos derivados de 3,3-biarilpiperidina y 2,2-biarilmorfolina, composicion y uso de los mismos
ES2123149T3 (es) Derivados de perhidroisoindol como antagonistas de la substancia p.
UY26086A1 (es) Procedimientos e intermedios para preparar compuestos anticancerosos
PT896533E (pt) Pentafluorobenzenosulfonamidas e analogos
ECSP003682A (es) Compuestos para el tratamiento de la isquemia
TR200003011T2 (tr) Yeni dihidropirimidinler.
ES2133324T3 (es) Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y metodos de uso.
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
UY28377A1 (es) Agentes terapeuticos
BR0114379A (pt) Derivados de c-ciclohexilmetilamina substituìdos
SE9801494D0 (sv) Novel use
MX9401224A (es) Procedimiento para la obtencion de 1, 1, 1, 3, 3- pentafluorpropano.
TR200000153T2 (tr) İl-5 inhibite eden 6-azaurasil türevleri.
ECSP044971A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson
BR0115139A (pt) Compostos bis-heterocìclicos com atividade antitumor e quimiossensibilizante
ES2189956T3 (es) Derivados de quinolina, procedimientos para su preparacion y su uso como medicamentos.
BR9713176A (pt) Benzotiofenos amorfos,métodos de preparação e métodos de uso
BR9912816A (pt) Composição terapêutica à base de flavonóides, tencionada para uso no tratamento de tumores por agentes citotóxicos